Abstract:Assessment of tumour budding using haematoxylin and eosin (H&E) and cytokeratin (CK) staining is feasible in rectal cancer biopsy and post‐neoadjuvant therapy‐treated resection specimens, and is associated with LNM and worse survival outcomes. Future management strategies for rectal cancer might be tailored to incorporate these findings. Background Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility of TB assessment in the setting of neoadjuvant treatment. Methods and results A single‐centre, retrospective cohort study was conducted. TB was assessed using the hot‐spot International Tumour Budding Consortium (ITBCC) method and classified by the revised ITBCC criteria. Haematoxylin and eosin (H&E) and AE1/AE3 cytokeratin (CK) stains for ITB (intratumoural budding) in biopsies with PTB (peritumoural budding) and ITB (intratumoural budding) in resection specimens were compared. Logistic regression assessed budding as predictors of lymph node metastasis (LNM). Cox regression and Kaplan–Meier analyses investigated their utility as a predictor of disease‐free (DFS) and overall (OS) survival. A total of 146 patients were included; 91 were male (62.3%). Thirty‐seven cases (25.3%) had ITB on H&E and 79 (54.1%) had ITB on CK assessment of biopsy tissue. In univariable analysis, H&E ITB [odds (OR) = 2.709, 95% confidence interval (CI) = 1.261–5.822, P = 0.011] and CK ITB (OR = 2.165, 95% CI = 1.076–4.357, P = 0.030) predicted LNM. Biopsy‐assessed H&E ITB (OR = 2.749, 95% CI = 1.258–6.528, P = 0.022) was an independent predictor of LNM. In Kaplan–Meier analysis, ITB identified on biopsy was associated with worse OS (H&E, P = 0.003, CK: P = 0.009) and DFS (H&E, P = 0.012; CK, P = 0.045). In resection specimens, CK PTB was associated with worse OS (P = 0.047), and both CK PTB and ITB with worse DFS (PTB, P = 0.014; ITB: P = 0.019). In multivariable analysis H&E ITB predicted OS (HR = 2.930, 95% CI = 1.261–6.809) and DFS (HR = 2.072, 95% CI = 1.031–4.164). CK PTB grading on resection also independently predicted OS (HR = 3.417, 95% CI = 1.45–8.053, P = 0.005). Conclusion Assessment of TB using H&E and CK may be feasible in rectal cancer biopsy and post‐neoadjuvant therapy‐treated resection specimens and is associated with LNM and worse survival outcomes. Future management strategies for rectal cancer might be tailored to incorporate these findings.

Tumor budding in pre-neoadjuvant biopsy and post-neoadjuvant resection specimens is associated with poor prognosis in intrahepatic cholangiocarcinoma—a cohort study of 147 cases by modified ITBCC criteria

Tumor Budding is a Meaningful Prognostic Marker in Patients with Hepatocellular Carcinoma after Curative Hepatectomy

High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection

Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer

Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant‐treated rectal adenocarcinoma

Prognostic significance of tumor budding in biliary tract cancer

High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer

Differential effect of tumor budding on the benefit of adjuvant chemotherapy in stage II colorectal cancer: a retrospective observational study

Increased Blood-Based Intratumor Heterogeneity (bith) is Associated with Unfavorable Outcomes of Immune Checkpoint Inhibitors Plus Chemotherapy in Non-Small Cell Lung Cancer

Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?

Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study

Association of tumor budding and tumor infiltrating lymphocytes with clinicopathological parameters in gallbladder carcinoma

Prognostic Significance of Intratumoral and Peritumoral Budding in Distal Extrahepatic Bile Duct Carcinoma

Comparison between Peritumoral and Intratumoral Budding in Colorectal Cancer

Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma

Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer

High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma

Predicting prognosis in intrahepatic cholangiocarcinoma by the histopathological features

Abstract 6133: Intratumoral budding in pretreatment biopsies can predict prognosis and neoadjuvant therapy response among the tumor microenvironmental components in colorectal adenocarcinoma

Tumor Budding, p53, and DNA Mismatch Repair Markers in Sinonasal Intestinal-Type Adenocarcinoma: A Retrospective Study Supports the Adverse Prognostic Impact of Tumor Budding

Validation of the International Tumor Budding Consensus Conference (2016) recommendations in oral tongue squamous cell carcinoma.